Sangamo and Novartis partner on gene therapies for autism 03-Aug-2020 By Ben Hargreaves The two companies will develop three neurodevelopmental targets, using the former’s zinc-finger technology.
Kite gets second CAR-T approval, 96% manufacturing success rate 30-Jul-2020 By Ben Hargreaves Kite becomes the first company to have two approved CAR-T treatments, with its second targeting rare form of lymphoma.
MaxCyte partners with Apeiron for siRNA immunotherapy 22-Jul-2020 By Ben Hargreaves MaxCyte and Apeiron enter agreement for the use of engineering equipment for the development of a cell therapy.
Ireland calls attention to cell and gene infrastructure 22-Jul-2020 By Ben Hargreaves A report by IDA outlines investment made by biopharma into cell and gene development and manufacturing capabilities.
MassBio wants improved manufacturing to maintain biohub position 22-Jul-2020 By Ben Hargreaves The organization calls for capabilities to manufacture advanced therapeutics, such as cell and gene therapies.
Marken adds multiple depot locations, boosts capacity for cell and gene 21-Jul-2020 By Ben Hargreaves Marken announces the addition of two depots in the US and Ukraine, as well as logistics branches in Ireland and the Netherlands.
BeiGene launches $2bn share offering, backed by Amgen 13-Jul-2020 By Ben Hargreaves Chinese biotech plans to raise the sum as working capital, as it looks to progress its pipeline.
Sarepta licenses therapy to boost gene therapies 06-Jul-2020 By Ben Hargreaves Sarepta signs agreement with Hansa to use its treatment as part of a gene therapy treatment schedule.
Takeda expands in gene therapy with $900m R&D deal 02-Jul-2020 By Ben Hargreaves Takeda signs R&D agreement with Carmine for the development of two non-viral gene therapies.
CSL Behring in $450m spend on hemophilia gene therapy 30-Jun-2020 By Ben Hargreaves The company buys the global rights to a gene therapy currently going through Phase III trials.
Hired & Retired: From big pharma to mid-sized leadership 24-Jun-2020 By Ben Hargreaves This month featured executives making the switch from big pharma to take on leadership positions at mid-sized companies.
Biotech launches with $300m and ‘high precision’ cell therapies 23-Jun-2020 By Ben Hargreaves Orca Bio emerges with a manufacturing platform that it claims produces cell therapies with an ‘unprecedented turnaround time’.
Emergent in $75m expansion into viral vectors and gene therapy 22-Jun-2020 By Ben Hargreaves The company will buildout its Massachusetts facility to provide CDMO services for viral vector and gene therapies.
TreeFrog opens stem cell manufacturing facility 16-Jun-2020 By Ben Hargreaves The startup completes work on facility to produce stem cell therapies in-house.
Kite able to manufacture Yescarta in Europe after approval 16-Jun-2020 By Ben Hargreaves The cell therapy can now be produced for 4,000 patients per year in Europe.
